Sharon McDermott currently serves as the Senior Director of Biostatistics at Travere Therapeutics, where she plays a pivotal role in advancing the company’s mission to deliver innovative therapies for rare diseases. With a robust background in statistical analysis and clinical trial design, Sharon is instrumental...
Sharon McDermott currently serves as the Senior Director of Biostatistics at Travere Therapeutics, where she plays a pivotal role in advancing the company’s mission to deliver innovative therapies for rare diseases. With a robust background in statistical analysis and clinical trial design, Sharon is instrumental in enhancing the overall efficiency and best practices within the Biometrics group. Her expertise encompasses a wide array of therapeutic areas, with a particular focus on Major Depressive Disorder, where she has contributed significantly to the statistical methodologies that underpin clinical studies.
In her role, Sharon provides critical statistical and strategic input for study reports, regulatory submissions, and publications, ensuring that the data generated is not only robust but also aligned with regulatory expectations. She is adept at performing complex statistical analyses, which are essential for interpreting clinical trial results and informing decision-making processes. Furthermore, Sharon is committed to the professional development of her team, actively mentoring Biometrics personnel and fostering an environment of continuous learning and constructive feedback.
Her strong communication skills and self-confidence enable her to effectively negotiate and collaborate with cross-functional teams, enhancing productivity and driving business development initiatives. Sharon’s leadership in statistical reporting and clinical data management has positioned her as a key player in the pharmaceutical industry, where she continues to build a strong network of researchers. By staying current with the latest advancements in biostatistics and technology, Sharon ensures that Travere Therapeutics remains at the forefront of innovation in clinical trial methodologies, ultimately contributing to the successful development of life-changing therapies.
